September 20, 2018
CRISPR Therapeutics (CRSP) prices 4.210526 M shares at $47.50, a $200 M offering with a $30 M underwriting option
August 8, 2018
REGENXBIO (RGNX) proposes a $175 M offering
July 25, 2018
bluebird bio (BLUE) prices 3.348 M share offering at $162.50
June 14, 2018
Verastem Oncology (VSTM) a registered stock sale
May 31, 2018
Vericel (VCEL) proposes 5 M share $65 M offering at $13.00
May 16, 2018
Cellectis SA (CLLS) subsidiary Calyxt (CLXT) proposes offering
May 16, 2018
Cesca Therapeutics (KOOL) prices 9.16 M or $5.5 M offering at $0.60 - SELL
May 16, 2018
Verastem Oncology (VSTM) proposes $35 M offering priced at $4.50 - SELL
May 9, 2018
AxoGen (AXGN) now proposes a 3 M share offering priced at $41.00 - SELL
May 2, 2018
uniQure N.V. (QURE) proposes 4.5 M share offering priced at $28.50
April 26, 2018
Sangamo Therapeutics (SGMO) prices $200 M offering at $16.25 - SELL
April 16, 2018
Bellicum Pharmaceuticals (BLCM) prices 7 M share offering at $7.50
April 9, 2018
Cesca Therapeutics (KOOL) proposes a $10 M unit and attached warrant offering in new prospectus
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
March 26, 2018
Cesca Therapeutics (KOOL) proposes RDO of 609,636 shares at $2.27 with warrants
February 7, 2018
Adverum Biotechnologies (ADVM) closed $69 M offering
January 22, 2018
Histogenics Corporation (HSGX) Prices Registered Direct Offering (RDO) of 2,340,430 shares at $2.35
January 22, 2018
Stemline Therapeutics (STML) proposes 3.7 M share offering
January 16, 2018
Intrexon (XON) Prices 6 M share offering at $12.50
January 12, 2018
AquaBounty Technologies (AQB) 3.69 M share, $12 M offering priced at $3.25
December 19, 2017
Northwest Bio (NWBO) Just another Ponzi financing scheme
December 14, 2017
Verastem (VSTM) proposes $25 M offering
December 13, 2017
Fate Therapeutics (FATE) closes $42.9 M offering at $4.20
December 12, 2017
bluebird bio (BLUE) Prices 3.343 M share offering at $185.00
December 11, 2017
VistaGen (VTGN) closes 10 M share offering at $1.50 with 100% warrant coverage
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.